We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed the most recent trading day at $595.41, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.48% for the day. Elsewhere, the Dow saw a downswing of 0.29%, while the tech-heavy Nasdaq depreciated by 0.56%.
Shares of the provider of outsourced clinical development services have appreciated by 1.56% over the course of the past month, outperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%.
Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $708.75 million, reflecting a 7.4% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 33.5. This signifies a premium in comparison to the average Forward P/E of 16.92 for its industry.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.62. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.44.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Medpace (MEDP - Free Report) closed the most recent trading day at $595.41, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.48% for the day. Elsewhere, the Dow saw a downswing of 0.29%, while the tech-heavy Nasdaq depreciated by 0.56%.
Shares of the provider of outsourced clinical development services have appreciated by 1.56% over the course of the past month, outperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%.
Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $708.75 million, reflecting a 7.4% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace is holding a Zacks Rank of #2 (Buy) right now.
In terms of valuation, Medpace is currently trading at a Forward P/E ratio of 33.5. This signifies a premium in comparison to the average Forward P/E of 16.92 for its industry.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.62. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.44.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.